Document Type : Original Article
Authors
- Soraya Shadmanfar 1
- Gholamhosein Alishiri 2
- Noushin Bayat 3
- Morteza Izadi 1
- Ahmad Salimzadeh 4
- Abdolrahman Rostamian 5
- Shahla Abolghasemi 6
- Mohammad Hossein Azimzadeh Ardebili 7
- Zeynab Rastgar Moqaddam 8
- Marjan Hasani 7
- Ehsan Rahmanian 7
- Helia Iranpanah 9
- Ghodrat Allah Islami 7
- Amin Saburi 2
1 Health Research Center, Life Style Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran
2 Chemical Injuries Research Center, Systems Biology and Poisonings Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran
3 Exercise Physiology Research Center, Life Style Institute, Baqyiatallah University of Medical Sciences, Tehran, Iran
4 Sina Hospital, Rheumatology Research Center, Tehran University of Medical Sciences, Tehran, Iran
5 Department of Rheumatology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
6 Department of Rheumatology, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran
7 Student Research Committee, Baqiyatallah University of Medical Sciences, Tehran, Iran
8 Iran University of Medical Science, Tehran, Iran
9 Shahid Beheshti University of Medical Sciences, Tehran, Iran
Abstract
Background: Among suggested medications for the treatment of COVID-19, chloroquine derivates and angiotensin-converting–enzyme inhibitors (ACEIs)/angiotensin II type 1 receptor blockers (ARBs) are the two medications with conflicting effects on the development of the disease.
Objectives: The present study aimed to evaluate COVID-19 in patients with rheumatic diseases receiving chloroquine derivate.
Methods: Every patient with proven rheumatologic diseases registered in two referral centers in Tehran and Alborz, Iran was enrolled in the present descriptive cross-sectional study between May and June 2020. At first, the symptoms of COVID-19 were assessed, and if a case had suspicious symptoms, reverse transcription-polymerase chain reaction (RT-PCR) COVID-19 tests were done. Demographic and clinical data are documented for every patient. Then, the patients were grouped once according to their COVID-19 infection status and another time according to their hydroxychloroquine use.
Results: 1159 patients enrolled in the study with a mean age of 49.39 years. Frequency of hypertension was 22.17 %, diabetics (9.49%) and 20 (1.7%) patients were positive for COVID-19 testing. The most common symptoms of the COVID-19 positive cases were cough (5.2%) and fever (4%). There was no significant difference in receiving ACEIs/ARBs or other medications between COVID-19 positive or negative patients. Among the patients receiving hydroxychloroquine, 15 patients (1.7%) had proved COVID-19 versus 5 patients (1.7%) who were not receiving these medications (P>0.999).
Conclusion: The present study demonstrated that receiving ARBs or ACEIs was not different among patients with or without COVID-19. Moreover, receiving chloroquine derivate was not related to the development of COVID-19 in patients with rheumatologic disorders.
Keywords
)
